{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:33:15Z","timestamp":1789943595257,"version":"4.0.1"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.neuropharm.2014.01.014","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T16:01:55Z","timestamp":1390233715000},"page":"688-706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys"],"prefix":"10.1016","volume":"79","author":[{"given":"Nicolas","family":"Morin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.01.014_bib1","unstructured":"Addex Therapeutics, 2012 Mar 21. Geneva, Switzerland (Media Release) (online).\u00a0Available from URL: http:\/\/www.addextherapeutics.com\/investors\/pressreleases\/newsdetails\/article\/addex-reports-positive-top-line-phase-iia-datafor-dipraglurant-in-parkinsons-disease-levodopa-indu\/ (accessed 11.02.13.)."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0006-8993(93)91069-5","article-title":"Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment","volume":"625","author":"Alexander","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00001756-199410270-00037","article-title":"Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys","volume":"5","author":"Asselin","year":"1994","journal-title":"NeuroReport"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2006.06.038","article-title":"Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"61","author":"Aubert","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tips.2007.02.006","article-title":"The Akt-GSK-3 signaling cascade in the actions of dopamine","volume":"28","author":"Beaulieu","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2005.05.012","article-title":"An Akt\/beta-arrestin 2\/PP2A signaling complex mediates dopaminergic neurotransmission and behavior","volume":"122","author":"Beaulieu","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib11","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.15-12-07821.1995","article-title":"Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain","volume":"15","author":"Bergson","year":"1995","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1523\/JNEUROSCI.1541-11.2012","article-title":"L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor","volume":"32","author":"Berthet","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00726-006-0320-3","article-title":"Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease","volume":"32","author":"Bonsi","year":"2007","journal-title":"Amino Acids"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib17","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S1471-1931(00)00016-1","article-title":"PET studies and motor complications in Parkinson's disease","volume":"23","author":"Brooks","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1471-4159.2007.04586.x","article-title":"Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum","volume":"102","author":"Bychkov","year":"2007","journal-title":"J.\u00a0Neurochem"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias","volume":"61","author":"Calon","year":"2002","journal-title":"J.\u00a0Neuropath Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0006-8993(95)00229-J","article-title":"Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex","volume":"680","author":"Calon","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1460-9568.1994.tb00328.x","article-title":"Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum","volume":"6","author":"Campbell","year":"1994","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib23","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib25","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-328X(01)00217-0","article-title":"Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum","volume":"94","author":"Choe","year":"2001","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib27","first-page":"299","article-title":"Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury","volume":"20","author":"Chong","year":"2005","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.877576","article-title":"Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity","volume":"197","author":"Creese","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(88)90750-9","article-title":"Behavioral and biochemical effect of chronic treatment with D-1 and\/or D-2 dopamine agonists in MPTP monkeys","volume":"150","author":"Falardeau","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1042\/BST0321025","article-title":"Oligomeric assembly of dopamine D1 and glutamate NMDA receptors: molecular mechanisms and functional implications","volume":"32","author":"Fiorentini","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/mol.105.016667","article-title":"Loss of synaptic D1 dopamine\/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat","volume":"69","author":"Fiorentini","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.brainresrev.2007.11.007","article-title":"Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology","volume":"58","author":"Fuxe","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94802-5","article-title":"Effect of chronic treatment of MPTP monkeys with dopamine D-1 and\/or D- 2 receptor agonists","volume":"178","author":"Gagnon","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0278-5846(95)00110-H","article-title":"Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors","volume":"19","author":"Gagnon","year":"1995","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00429-012-0405-6","article-title":"Combinatorial topography and cell-type specific regulation of the ERK pathway by dopaminergic agonists in the mouse striatum","volume":"218","author":"Gangarossa","year":"2013","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.ne.15.030192.001441","article-title":"The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia","volume":"15","author":"Gerfen","year":"1992","journal-title":"Annu Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib43","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib44","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1523\/JNEUROSCI.11-04-01016.1991","article-title":"Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis","volume":"11","author":"Gerfen","year":"1991","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0006-8993(96)00157-6","article-title":"Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys","volume":"719","author":"Goulet","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0278-5846(00)00096-8","article-title":"Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys","volume":"24","author":"Goulet","year":"2000","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0306-4522(96)00689-6","article-title":"Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis","volume":"79","author":"Goulet","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0006-8993(90)90440-M","article-title":"Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis)","volume":"514","author":"Graham","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0006-8993(93)90694-I","article-title":"Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism","volume":"602","author":"Graham","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib50","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib51","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.294.5544.1024","article-title":"The neurobiology of slow synaptic transmission","volume":"294","author":"Greengard","year":"2001","journal-title":"Sci. (New York, N.Y.)"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys","volume":"17","author":"Gregoire","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib53","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(99)00482-3","article-title":"Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958","volume":"378","author":"Grondin","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pneurobio.2004.09.005","article-title":"Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases","volume":"74","author":"Gubellini","year":"2004","journal-title":"Prog. Neurobiol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2014.01.014_bib56","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.parkreldis.2004.11.005","article-title":"Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors","volume":"11","author":"Guigoni","year":"2005","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib57","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.nbd.2007.02.001","article-title":"Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates","volume":"26","author":"Guigoni","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ana.410190510","article-title":"Dopamine D2 receptor density remains constant in treated Parkinson's disease","volume":"19","author":"Guttman","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib60","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0014-4886(03)00064-5","article-title":"Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease","volume":"183","author":"Henry","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-328X(96)00157-X","article-title":"Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys","volume":"42","author":"Herrero","year":"1996","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib62","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0306-4522(95)00120-8","article-title":"Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum","volume":"68","author":"Herrero","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0891-0618(01)00122-3","article-title":"D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain","volume":"22","author":"Hurd","year":"2001","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-009-1600-x","article-title":"Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats","volume":"206","author":"Jimenez","year":"2009","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib68","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson's disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib69","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therap."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.410340413","article-title":"Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia","volume":"34","author":"Klockgether","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000065951","article-title":"Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain","volume":"76","author":"Landry","year":"2002","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib72","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cne.902890104","article-title":"Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry","volume":"289","author":"Lavoie","year":"1989","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0092-8674(02)00962-5","article-title":"Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor","volume":"111","author":"Lee","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/273059a0","article-title":"Receptor basis for dopaminergic supersensitivity in Parkinson's disease","volume":"273","author":"Lee","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib75","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib76","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.3292-06.2006","article-title":"RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation","volume":"26","author":"Malagelada","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib77","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1523\/JNEUROSCI.4360-04.2005","article-title":"The scaffold protein Homer1b\/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons","volume":"25","author":"Mao","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of L-dopa: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib81","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib83","article-title":"Modeling dyskinesia in animal models\u00a0of Parkinson disease","author":"Morin","year":"2013","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.20654","article-title":"Prevention of levodopa-induced dyskinesias by a selective NR1A\/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin","volume":"21","author":"Morissette","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib86","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0026-895X(25)09534-3","article-title":"Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine","volume":"50","author":"Morissette","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","article-title":"Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy","volume":"49","author":"Morissette","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib88","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1471-4159.1999.0720682.x","article-title":"Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists","volume":"72","author":"Morissette","year":"1999","journal-title":"J.\u00a0Neurochem"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib89","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.pnpbp.2009.12.011","article-title":"Striatal Akt\/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys","volume":"34","author":"Morissette","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib90","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/mds.10256","article-title":"Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats","volume":"17","author":"Muriel","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib91","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1531-8249(199907)46:1<103::AID-ANA15>3.0.CO;2-Z","article-title":"Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease","volume":"46","author":"Muriel","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib92","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0306-4522(94)90272-0","article-title":"Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion","volume":"60","author":"Nisenbaum","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib93","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-3940(95)12229-X","article-title":"Acute treatment with the N-methyl-D-aspartate receptor antagonist MK-801: effect of concurrent administration of haloperidol or scopolamine on preproenkephalin mRNA levels of the striatum and nucleus accumbens of the rat brain","volume":"202","author":"Noailles","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib94","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-4159.2010.06635.x","article-title":"Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys","volume":"113","author":"Ouattara","year":"2010","journal-title":"J.\u00a0Neurochem"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib95","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib96","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1046\/j.1471-4159.2001.00179.x","article-title":"Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes","volume":"76","author":"Page","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0301-0082(95)80010-6","article-title":"Chemical anatomy of primate basal ganglia","volume":"46","author":"Parent","year":"1995","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib98","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pavon","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib99","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4615-1809-9_4","article-title":"MAP kinase-dependent pathways in cell cycle control","volume":"1","author":"Pelech","year":"1995","journal-title":"Prog. Cell. Cycle Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib100","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1471-4159.1992.tb10939.x","article-title":"Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease","volume":"58","author":"Pifl","year":"1992","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib101","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0022-510X(79)90021-2","article-title":"Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease","volume":"43","author":"Quik","year":"1979","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01664007","article-title":"Dopamine receptors in the Parkinsonian brain","volume":"51","author":"Rinne","year":"1981","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib103","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib104","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Therap."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib105","first-page":"101","article-title":"Wnt factors in axonal remodelling and synaptogenesis","volume":"65","author":"Salinas","year":"1999","journal-title":"Biochem Soc. Symp."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib106","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0072-9752(07)83002-8","article-title":"Functional neurochemistry of the basal ganglia","volume":"83","author":"Samadi","year":"2007","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib108","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib109","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib110","first-page":"720","article-title":"Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes","volume":"41","author":"Shaw","year":"1998","journal-title":"Genome"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp.56.5.467","article-title":"Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study","volume":"56","author":"Shinotoh","year":"1993","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib112","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-138-8-200304150-00013","article-title":"Update on Parkinson disease","volume":"138","author":"Siderowf","year":"2003","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib113","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0006-8993(89)91205-5","article-title":"Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey","volume":"482","author":"Smith","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s002210050545","article-title":"Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior","volume":"123","author":"Steiner","year":"1998","journal-title":"Exp. Brain. Res."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib114","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov. Disord."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2014.01.014_bib115","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1002\/mds.22052","article-title":"Treatment of levodopa-induced motor complications","volume":"23","author":"Stocchi","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib116","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cne.902220208","article-title":"A\u00a0stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)","volume":"222","author":"Szabo","year":"1984","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib117","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuropharm.2009.06.030","article-title":"Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides","volume":"58","author":"Tamim","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib118","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0306-4522(02)00535-3","article-title":"Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets","volume":"115","author":"Tel","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib119","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pneurobio.2008.05.003","article-title":"Progress in Parkinson's disease \u2013 where do we stand?","volume":"85","author":"Toulouse","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib120","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1523\/JNEUROSCI.08-12-04755.1988","article-title":"Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents","volume":"8","author":"Uhl","year":"1988","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib121","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib122","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.expneurol.2008.09.025","article-title":"Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys","volume":"215","author":"Villalba","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib123","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.neuroscience.2009.07.060","article-title":"Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats","volume":"163","author":"Yamamoto","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.01.014_bib124","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.1073\/pnas.83.24.9827","article-title":"Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain","volume":"83","author":"Young","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.01.014_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2006.02.009","article-title":"Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction","volume":"84","author":"Zhao","year":"2006","journal-title":"Schizophr. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:16:42Z","timestamp":1746116202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":124,"alternative-id":["S0028390814000215"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.01.014","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}